scholarly journals Scoring the Severity of Atopic Dermatitis: Three Item Severity Score as a Rough System for Daily Practice and as a Pre-screening Tool for Studies

1999 ◽  
Vol 79 (5) ◽  
pp. 356-359 ◽  
Author(s):  
A. Wolkerstorfer, F. B. De Waard van d
2020 ◽  
Vol 23 ◽  
pp. 86-99 ◽  
Author(s):  
Katsuhiko Matsui ◽  
Yuki Nojima ◽  
Yuka Kajiwara ◽  
Kana Busujima ◽  
Yuki Mori

Background: Langerhans cells (LCs) polarize the immune milieu towards a T helper type (Th) 1 or Th2 immune response. We investigated the effects of selected tetracyclines on Th cells development mediated by LCs, and their implications for the treatment of atopic dermatitis (AD). Methods: Mice were primed with ovalbumin (OVA) peptide-pulsed LCs, which had been treated with each antibiotic, via the hind footpad. After 5 days, the Th1/Th2 cytokine response in the popliteal lymph nodes was investigated by enzyme-linked immunosorbent assay. The expression of cell surface molecules on LCs was investigated using reverse transcriptase polymerase chain reaction. The therapeutic effects of a selected antibiotic on AD-like skin lesions of NC/Nga mice were assessed in terms of the skin severity score, histological changes in the lesioned skin, the serum level of total IgE, and expression of Th1/Th2 cytokines in lymph nodes and skin lesions. Results: Antibiotic-treated, OVA peptide-pulsed LCs inhibited development of Th2 cells but not Th1 cells. This was accompanied by suppression of T-cell immunoglobulin and mucin domain-containing protein (TIM)-4 expression in LCs. Doxycycline had the greatest activity against Staphylococcus aureus strains isolated from skin lesions of patients with AD, and a strong inhibitory effect on Th2 cell development. Doxycycline suppressed the increase in the skin severity score during the acute phase in NC/Nga mice similar to betamethasone. This suppressive effect was associated with a decrease in the serum IgE level and production of Th2 cytokines in auricular lymph node cells and skin lesions. Conclusion: Topical application of doxycycline to AD lesions would act on both superficial S. aureus colonization and epidermal LCs, thus possibly inhibiting the development of Th2 cells in vivo, with benefits for control of acute inflammation in AD.


2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Rajendra Karki ◽  
Myung-A Jung ◽  
Keuk-Jun Kim ◽  
Dong-Wook Kim

Atopic dermatitis (AD) is a chronic inflammatory skin disease which has a complex etiology that encompasses immunologic responses. The study was carried out to examine the effect ofNelumbo nucifera(Gaertn.) leaf (NL) on the AD-like skin lesion induced by repeated epicutaneous application of 2,4-dinitrochlorobenzene (DNCB) on the dorsal skin of NC/Nga mice. Three different doses of NL (5, 25, and 50 mg/mice/day) were administered orally from the day of sensitization with DNCB for 4 weeks. The efficacy of NL was judged by histopathological examination, blood IgE level, measurement of transepidermal water loss (TEWL), scratching behavior, and skin severity score. NL resulted in the suppression of clinical severity score, TEWL, scratching behavior, and blood IgE level. Histopathologic analyses revealed that thickening of the epidermis and mast cell degranulation was significantly reduced in NL group. These results suggest that NL may be a useful natural resource for the management of AD.


2006 ◽  
Vol 7 (2) ◽  
pp. 121-131 ◽  
Author(s):  
Jann L??bbe ◽  
Sheila F Friedlander ◽  
Bernard Cribier ◽  
Marie-Anne Morren ◽  
Amaro Garc??a-D??ez ◽  
...  

2017 ◽  
Vol 97 (8) ◽  
pp. 955-956 ◽  
Author(s):  
J Daguzé ◽  
H Aubert ◽  
C Bernier ◽  
A Gaultier ◽  
J Nguyen ◽  
...  

2007 ◽  
Vol 5 (10) ◽  
pp. 908-914 ◽  
Author(s):  
Thomas A. Luger ◽  
Harald Gollnick ◽  
Thomas Schwennesen ◽  
Raphael Bextermöller ◽  
Siegfried Freytag ◽  
...  

Author(s):  
José Eizayaga

If there were one lacking or insufficient issue which conscious medical orientated homeopaths could regret, it would be probably high quality clinical research. A big part of the homeopathic community still insists in the traditional ways of building knowledge, leading us nowhere. There is now an agreement between clinical researchers that there have been done enough efforts with Randomized Control Trials (RCT). But what we need today is good quality scientific research that could improve our daily practice. This article introduce the REDIMEH, an Ibero-American Integrative Network for Clinical Research in Homeopathy, horizontal in structure, with no political objectives, with the only intention of joining efforts in order to obtain enough clinical data to draw out valid conclusions. Keywords: REDIMED, atopic dermatitis, clinical research.  Projeto REDIMED: Red Integrada Ibero-Americana para Pesquisa Clínica em Homeopatia ResumoSe pudermos apontar uma questão, a qual os verdadeiros médicos homeopatas podem se lamentar, esta deveria ser a falta ou insuficiéncia de pesquisas clínicas de alta qualidade. Uma grande parte da comunidade homeopática ainda insiste nas formas tradicionais de construção de conhecimento, levando-nos a lugar algum. Existem pontos bem estabelecidos pelos pesquisadores clínicos que tem se esforçado muito com a realização de Ensaios Controlados Randomizados (RCT). O que mais precisamos hoje é de investigação científica de boa qualidade, que possa melhorar a nossa prática diária. Este artigo apresenta o projeto REDIMEH, uma Rede Integrada Ibero-Americana para Pesquisa Clínica em Homeopatia, de estrutura horizontal, sem objetivos políticos, com a intenção de unir esforços no sentido de obter dados clínicos suficientes para chegarmos a conclusões válidas para a prática clínica diária. Palavras-chave: REDIMED, dermatite atópica, investigação clínica.  Proyecto REDIMEH: Red Iberoamericana Integrativa de Investigación Clínica en Homeopatía ResumenSi hubiera uma cuestión de la cual los médicos homeopatas podrían pesar, sería probablemente la investigación clínica de alta calidad. Una gran parte de la comunidad homeopática sigue insistiendo en las formas tradicionales de construcción del conocimiento, que nos conduce a ninguna parte. En la actualidad, existe un acuerdo entre los investigadores clínicos, que ya se han hecho lo suficiente con los esfuerzos de control de ensayos aleatorios (RCT). Pero lo que necesitamos hoy es la investigación científica de buena calidad que pueda mejorar nuestra práctica diaria. Este artículo presentará el REDIMEH, uma Red Iberoamericana Integrativa de Investigación Clínica en Homeopatía, con una estructura horizontal, sin objetivos políticos, con la única intención de unir esfuerzos con el propósito de obtener datos clínicos suficientes para sacar conclusiones válidas. Palabras-clave: REDIMED, dermatitis atópica, investigación clínica  Correspondence author: Jose Eizayaga, [email protected], www.maimonides.edu How to cite this article: Eizayaga J. REDIMEH Project: Ibero-American Integrative Network for Clinical Research in Homeopathy. Int J High Dilution Res [online]. 2009 [cited YYYY Month dd]; 8(27): 50-52. Available from: http://journal.giri-society.org/index.php/ijhdr/article/view/340/392.  


2021 ◽  
Author(s):  
Harmen R. Moes ◽  
Jolien ten Kate ◽  
Axel T. Portman ◽  
Barbera van Harten ◽  
Mirjam E. van Kesteren ◽  
...  

AbstractObjectivesTo develop a screening tool for timely referral for advanced therapy (AT) in patients with Parkinson’s disease (PD), and to compare the newly-developed tool with the published 5-2-1 criteria.DesignCross-sectional, diagnostic, observational study and multivariable logistic regression analysis for item selection.Setting8 hospitals in the Northern part of the Netherlands situated in the catchment area of a specialized movement disorder centre.Participants259 consecutive PD patients not yet on AT visiting the outpatient clinic of participating hospitals from February 2017 to July 2018.Predictors24 patient and disease characteristics as assessed by the treating neurologists, and scores on the NMS questionnaire.OutcomeApparent eligibility for referral for AT based on consensus by a panel of 5 experts in the field of AT.Results17 patients were deemed eligible for referral for AT (point prevalence: 6.6%). Presence of response fluctuations and troublesome dyskinesias were the strongest independent predictors of being eligible for referral. Both variables were included in the final model, as well as levodopa equivalent daily dose. Decision curve analysis showed that the new model outperformed the 5-2-1 criteria. A simple chart was constructed to provide guidance for referral. Discrimination of this simplified scoring system was good (AUC after bootstrapping: 0.97).ConclusionThe screening tool may improve efficiency of referral and subsequent treatment with AT in patients with PD. External validation is required prior to application in daily practice.Anyone who wishes to share, reuse, remix, or adapt this material must obtain permission from the corresponding author.


2007 ◽  
Vol 18 (3) ◽  
pp. 245-249 ◽  
Author(s):  
Giampaolo Ricci ◽  
Barbara Bendandi ◽  
Federica Bellini ◽  
Annalisa Patrizi ◽  
Massimo Masi

Sign in / Sign up

Export Citation Format

Share Document